Registered User Login
Asian Journal of Pharmacy and Technology
ISSN: 2231-5713(Online), 2231-5705(Print)
News & Conferences
Volume No. :
Issue No. :
ISSN Print :
ISSN Online :
Click to Login
Pharmacology of combined Mesalazine and Rifaximin Therapy to Inflammatory Bowel Disease
Prajapati Krishna V.
Jain Vinit C.
Prajapati Krishna V.1*, Dr. Jain Vinit C. 1, Ms. Prajapati Neelam2
1Department of Quality Assurance, Shree Dhanvantary Pharmacy College, Kim, Dist: Surat
2Assistant Professor, Department of Quality Assurance, Shree Dhanvantary Pharmacy College, Kim, Dist: Surat
This review article presents the pharmacology of combined Mesalazine and Rifaximin therapy especially in inflammatory bowel disease. Mesalazine is as used in anti-inflammatory agent, Non-Steroidal. Rifaximin is used in Gastrointestinal Agents, Anti-infective agent. The use of Rifaximin in combination with Mesalazine has been proved to provide beneficial effect in inflammatory bowel disease. The mechanism of Mesalazine and Rifaximin is quite different. Mesalamine and Rifaximin are two different types of drugs offering some symptomatic relief to the IBD patients. Mesalamine treats inflammation, whereas, Rifaximin reduces bio burden. Patent for combination of both drugs were approved by WIPO. The main objective of this review article is to provide pharmacological information of combined therapy of Mesalazine and Rifaximin to researcher in development of combined dosage form of this.
Mesalazine, Rifaximin, inflammatory bowel disease, Pharmacology.
Prajapati Krishna V., Jain Vinit C., Prajapati Neelam. Pharmacology of combined Mesalazine and Rifaximin Therapy to Inflammatory Bowel Disease . Asian J. Pharm. Tech. 2016; Vol. 6(1): 45-50.
Visitor's No. :